Nova Primary Blood Glucose Reference Analyzer Receives US FDA Clearance
|
By LabMedica International staff writers Posted on 31 Oct 2022 |

Nova Biomedical (Waltham, MA, USA) has received clearance from the U.S. Food and Drug Administration (FDA) for its Nova Primary as a blood glucose reference analyzer. Nova Primary fills the need for a new glucose reference analyzer to replace the discontinued YSI STAT PLUS 2300 Glucose and L-Lactate analyzer from YSI, Inc. (Yellow Springs, OH, USA).
Manufacturers of blood glucose measuring devices and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, YSI, Inc. no longer supports the analyzer, and its discontinuation has left a critical industry void. The Nova Primary analyzer fills that need. With the FDA clearance, Nova Primary is now available in the U.S. and worldwide. Like the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 20-900 mg/dL. It uses a small, 25 microliter venous whole blood or plasma sample which is internally diluted as in the YSI. Results are available in approximately 2 minutes.
Nova Primary's large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and number of samples remaining, eliminating the need for separate reagent bottles and daily monitoring of their levels. In clinical laboratory studies using venous whole blood and plasma, the Nova Primary demonstrated excellent correlation to the YSI 2300 and is traceable to NIST glucose standards. The Nova Primary uses a comma delimited (.csv) format data output that can be downloaded via the integral USB data port. The analyzer measures 17 in x 11 in x 18 in (44 cm x 28 cm x 46 cm).
"We at Nova Biomedical are pleased to offer the Nova Primary, an accurate, easy-to-use and modernized blood glucose reference analyzer for glucose device manufacturers and clinical diabetes researchers to replace the discontinued YSI Stat Plus glucose analyzer," said Matthew McRae, Nova Sales Product Line Manager.
Related Links:
Nova Biomedical
YSI, Inc.
Latest Industry News
- QIAGEN Showcases Integrated Sample-to-Insight Oncology Solutions at AACR 2026
- Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
- Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
- Beckman Coulter Gains CE Mark for Rapid Assay Distinguishing Bacterial vs Viral Infections
- Junction, GRAIL Enable Scalable Access to Multi-Cancer Detection Test
- GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
- Global Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
- Takara Bio USA and Hamilton Partner to Automate NGS Library Preparation
- Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
- Integrated DNA Technologies Expands into Clinical Diagnostics
- Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
- Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
- New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network
- MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
- Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparedness
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Framework Guides Targeted Immunotherapy Selection in Liver Cancer
Primary liver cancer, encompassing hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), is the world’s third-leading cause of cancer-related death, responsible for about 830,000 deaths... Read more
Collaboration Brings Rapid At-Home STI Testing with Virtual Follow-Up
Sexually transmitted infections (STIs) are often asymptomatic, and reliance on clinic-based testing can delay diagnosis and treatment. More than one million curable infections are acquired daily worldwide... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
Central nervous system (CNS) infections such as encephalitis, ventriculitis, and brain abscess are among the most time-sensitive diagnostic challenges in neurology. Standard testing can return negative... Read moreRapid Color Test Stratifies Virulent and Resistant Staph Strains
Staphylococcus aureus (golden staph) remains a leading cause of infection-related mortality worldwide, responsible for more than a million deaths each year. Rapidly distinguishing highly virulent or a... Read morePathology
view channel
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read more
Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. Identifying molecular... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more







